TJPC(SH:600488)2023-03-29 16:00Financial Performance - The company reported a total distributable profit of ¥856,451,168.44 as of December 31, 2022, with a proposed cash dividend of ¥0.10 per 10 shares, amounting to a total cash distribution of ¥10,963,626.80, resulting in a cash dividend payout ratio of 30.97%[4]. - The company achieved operating revenue of CNY 3.689 billion in 2022, a decrease of 1.59% compared to 2021[24]. - The net profit attributable to shareholders was CNY 35.41 million, down 27.25% from the previous year[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 203.92% to CNY 113.05 million[24]. - The basic earnings per share decreased by 28.89% to CNY 0.032, while the diluted earnings per share remained the same[22]. - The net cash flow from operating activities increased by 106.23% to CNY 653.52 million, driven by improved management of customer payment terms[23]. - The total assets increased by 4.82% to CNY 6.651 billion at the end of 2022[24]. - The company reported a total of 980,000 shares repurchased, with a total value of 686,000, resulting in a decrease of 294,000 shares[153]. Corporate Governance - The company emphasizes the importance of the accuracy and completeness of the annual report, with all board members present at the meeting[7]. - The company has a robust corporate governance structure, with independent boards and committees operating under legal and regulatory frameworks[148]. - The company has revised its governance policies to enhance compliance and reduce governance risks, ensuring timely and accurate information disclosure[146]. - The company has maintained a cash dividend policy since 2003, ensuring reasonable returns to investors annually[173]. - The company has a comprehensive assessment process for determining the remuneration of its directors and senior management[160]. - The company has established a remuneration committee to oversee the compensation of its directors and senior management[160]. - The company reported a total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 5.56 million yuan[160]. Risk Management - The company has provided a detailed analysis of potential risks in its report, particularly in the section discussing future developments and risks[6]. - The company is focusing on enhancing its marketing capabilities and risk awareness in compliance operations to strengthen market adaptability[39]. - The company is committed to strengthening project risk management to reduce the risks associated with new product development, thereby improving the success rate of R&D projects[139]. - The company is actively involved in risk assessment related to financial operations, ensuring compliance and stability[167]. Research and Development - Total R&D investment reached 183.19 million yuan, which is 4.97% of operating revenue, with 22.12% of the R&D costs capitalized[63]. - The company employed 500 R&D personnel, making up 19.46% of the total workforce[64]. - The company has several new drug developments in progress, including XP0020 for hypertension and XP0019 for autoimmune diseases, both classified as Class 3 chemical drugs and currently under review[92]. - The company is focusing on consistency evaluation for various products, including dexamethasone tablets, to ensure quality and efficacy in the market[89]. - The company is actively pursuing international registrations for its products, enhancing its global market presence and competitiveness[93]. Environmental Responsibility - The company invested 30.13 million yuan in environmental protection during the reporting period[187]. - The company has implemented real-time monitoring of environmental indicators through its SCADA data management platform to ensure compliance with environmental standards[140]. - The wastewater treatment facility operates normally, with average COD discharge at 177.731 mg/L, well below the standard limit of 500 mg/L[193]. - The company has established an emergency response plan for environmental incidents, with no incidents reported during the year[196]. - The company aims to continuously lower the incidence of workplace injuries and enhance employee safety through comprehensive training[188]. Market Position and Strategy - The company achieved a market share leadership in the U.S. for methylprednisolone acetate, with its first sterile lyophilized powder injection product successfully launched in the U.S. market[33]. - The company plans to actively develop new markets and continuously launch new products to enhance competitiveness[74]. - The company aims to become a leader in the steroid hormone and amino acid sectors, focusing on high-end product development and market expansion in both domestic and international markets[131]. - The company is committed to advancing its technology in the fields of steroid and amino acid drugs, focusing on the development of sterile raw materials and innovative formulations[132]. Operational Efficiency - The company implemented lean manufacturing principles, establishing nine cost-reduction targets to enhance operational efficiency and product yield[35]. - The company has established a talent pool and optimized performance assessment methods to enhance management efficiency and employee motivation[38]. - The company has achieved significant recognition, including being a national high-tech enterprise and the president unit of the National Steroid Hormone Industry Association[42]. - The company is addressing raw material price risks by enhancing supplier selection and procurement strategies to mitigate cost impacts[136]. Shareholder Engagement - The company held a total of 26 board meetings during the reporting period, with all directors attending the meetings as required[165]. - The company approved various proposals in shareholder meetings, including the initiation of foreign exchange derivative trading and amendments to the company’s articles of association[149]. - The company reported a reduction in shareholdings for several executives due to stock repurchase programs, with specific reductions of 48,000 shares for the acting chairman and 36,000 shares for the deputy general manager[151].